Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

Pfizer appears undervalued with a 6.8% dividend yield and low P/E ratio of 8.5x, but investors remain skeptical due to negative revenue growth over three years and upcoming patent cliffs, particularly for its blockbuster drug Eliquis. However, the company's deep pipeline in weight management and oncology, including promising candidates like MET-097i and PF-4404, could drive significant recovery if clinical trials succeed, making it potentially attractive for long-term income investors.